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Abstract 
Background: Lithium is widely used for the treatment of bipolar disorder. Due to its 
narrow therapeutic index and side-effect profile, regular monitoring of serum levels, 
renal and thyroid function has been recommended by all major guidelines on lithium 
use. Objectives: We investigated whether lithium monitoring during maintenance 
phase treatment in clinical practice meets the latest recommendation by the National 
Institute for Health and Clinical excellence (i.e. lithium levels between 0.6-1.0mmol/l 
and lithium level, thyroid and renal function tests every six months; NICE, 2014) in 
one of the largest mental health organisations in Europe, the South London and 
Maudsley (SLaM) NHS Foundation Trust. Methods: Retrospective data were 
extracted from SLaM’s Clinical Record Interactive Search (CRIS) system. Adult 
patients with a psychiatric disorder who were on lithium at any point during the 
period January 2012-January 2016 and had at least one lithium level test result in the 
system were included in the analyses. Results: 2639 lithium level tests results were 
retrieved for 412 patients. Overall, serum level was within the recommended range in 
50.7% of all tests, below the range in 42.4% and above in 6.9%. Lithium level, renal 
and thyroid function tests were performed at the recommended frequency of 6 months 
(or less) in 76.2%, 72.7% and 60.2% of patients, respectively. Conclusion: These 
data demonstrate that there is a gap between the NICE 2014 recommendation and 
lithium monitoring practice in secondary care, with a high number of lithium level 
results below the therapeutic minimum. Reminder strategies for secondary care 
practitioners, shared care agreements or a central registry for lithium users could 
improve monitoring performance. 
Keywords  
lithium, bipolar disorder, affective disorder, monitoring   
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Background 
Lithium has been widely used in clinical practice as a mood stabiliser after John Cade 
first observed its therapeutic effects for manic episodes (Cade, 1949). Since then, 
lithium has been licensed for the acute treatment of mania, for maintenance treatment 
in bipolar disorder and as augmentation to antidepressants for treatment resistant 
depression. There is ample evidence for its efficacy, tolerability and cost-effectiveness 
for all these indications (Storosum et al., 2007; Crossley and Bauer, 2007; Miura et 
al., 2014). All major international and UK treatment guidelines support the use of 
lithium for these indications.  In the context of bipolar disorder, lithium is considered 
the most effective treatment to date (Malhi and Outhred, 2016). In addition, large 
recent studies have shown that bipolar disorder patients taking lithium have a 
significantly reduced rate of self-harm and suicide-related events compared to patients 
on other treatments or no treatment (Hayes et al., 2016b; Song et al., 2017). 
 
Lithium has a narrow therapeutic index as serum levels below 0.4 mmol/l have no 
therapeutic benefit, levels ranging between 0.4-1.2 mmol/l are considered therapeutic 
(depending on the patient group), and toxicity can occur at 1.5 mmol/l. Table 1 
summarizes the recommendations put forward by the major international guidelines 
regarding optimal and toxic serum lithium levels. Of particular relevance to the UK 
are the National Institute for Health and Clinical excellence (NICE) and British 
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association for Psychopharmacology (BAP) guidelines for bipolar disorder, most 
recently updated in 2014 (NICE, 2014a) and 2016 (Goodwin et al., 2016), 
respectively. NICE recommends the optimal level for first use as an acute treatment to 
be between 0.6-0.8 mmol/l, for the acute treatment of relapse between 0.8-1.0 mmol/l 
and for maintenance treatment 0.6-0.8 mmol/l, with toxicity level unspecified. The 
BAP 2016 guideline recommends the same range for maintenance treatment as NICE 
(2014), with the optimal dose considered “the highest tolerated without significant 
adverse reactions”, and a higher recommended range for acute treatment of 1.0-1.5 
mmol/l, advised only for “unusual circumstances where alternative treatments have 
failed” (Goodwin et al., 2016). In BAP 2016 guideline for bipolar disorder toxic 
effects are considered to occur above 1.5 mmol/l, with life-threatening toxicity at 2.0 
mmol/l and above. Toxicity side-effects may present to multiple systems including 
gastrointestinal, renal, endocrine, cardiac and neuropsychiatric (Stahl, 2013). At high 
levels lithium may precipitate seizure, coma and death (Meyer and Quenzer, 2013). 
Nevertheless, recent data from various countries have shown that mortality rates from 
lithium intoxication are low: between 0-1% (Baird-Gunning et al., 2016; Mowry et 
al., 2013), with reports from the UK indicating 0% (Waring et al., 2007). 
 
Of particular concern with lithium toxicity or long-term lithium therapy (even if the 
levels are within the recommended range) are the potential adverse effects to the 
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kidney and thyroid. As lithium is almost entirely excreted in urine, conditions that 
influence kidney function or fluid balance can increase lithium accumulation (Paton et 
al., 2010). Lithium toxicity can affect glomerular and tubular renal function, induce 
nephrogenic diabetes insipidus and, in most severe cases, cause end-stage renal 
failure. The absolute risk of renal failure, however, has been calculated to be low at 
approximately 0.5% (McKnight et al., 2012). In the case of thyroid dysfunction, 
lithium accumulates in thyroid glands and inhibits the release of thyroid hormones, 
hence it can cause goitre, hypothyroidism and hyperthyroidism (Kraszewska et al., 
2014; Hayes et al., 2016a). A meta-analysis by McKnight et al. (2012) reported that 
the rate of hypothyroidism is increased almost six-fold in patients receiving lithium 
therapy compared to the general population. In addition, the risk of developing renal 
and thyroid side-effects from lithium is increased in patients who: (i) have comorbid 
conditions that affect these systems (Baird-Gunning et al., 2016); (ii) have a genetic 
predisposition (Gitlin, 2016); (iii) are taking drugs that interact with lithium (Joint 
Formulary, 2015); and (iv) are older than 50 years (Baird-Gunning et al., 2016). 
Therefore, testing of renal and thyroid function before the initiation of lithium 
treatment and regular monitoring thereafter, especially in groups at a high risk of 
toxicity, is warranted.  
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Table 1: Summary of the major international guidelines for lithium use as treatment of bipolar disorder 
Guideline Year  Phase Lithium 
range 
(mmol/l) 
Toxic level  
(mmol/l) 
Frequency of monitoring 
Lithium level Renal & Thyroid function 
BAP 2016 Acute 1.0-1.5 1.5 5 days after titration, then 
every 3 months in the first 
year and then every 6  
months 
Every 12 months 
   Maintenance 0.6-0.8   
      
      
CANMAT  2013 Acute  0.8-1.1 not specified 5 days after titration until 
2 consecutive levels are 
stable then every 3-6  
months 
4 weeks after initial dose 
and then every 12 months   Maintenance 0.8-1.1  
Maudsley 2015 Acute  1.0-1.2 1.5 7 days after dose change 
and every 6 months 
At baseline and then every 6 
months 
  Maintenance 0.6-1.0  
NICE 2014 Acute (first use) 0.6-0.8 not specified 7 days after dose change 
then weekly until stable; 
then every 3 months in the 
first year and every 6 
months thereafter 
At baseline and then every 6 
months   Acute (relapse) 0.8-1.0 not specified 
  Maintenance 0.6-0.8 not specified 
RANZCP 2015 Acute 0.8-1.2 not specified At baseline; every 6 
months in the first year 
and then every 12 months 
At baseline; every 6 months 
in the first year and then 
every 12 months 
  Maintenance 0.6-0.8 not specified 
WFSBP 2013 Acute mania 0.8-1.3 not specified Frequently until stable, 
then every 3-6 months 
Every 6-12 months 
 2009 Maintenance 0.6-1.2 not specified  
BAP: British Association for Psychopharmacology; CANMAT: Canadian Network for Mood and Anxiety Treatment; Maudsley: The Maudsley Prescribing Guidelines in Psychiatry; NICE: UK 
National Institute for Health and Care Excellence; RANZCP: Royal Australian and New Zealand  College of Psychiatrists; WFSBP: The World Federation  of Societies of Biological Psychiatry. 
7 
 
All major guidelines have included a recommendation on how frequently these tests need 
to be performed and the recommended interval varies significantly (Table 1). For 
example, NICE (2014) recommends performing tests for urea and electrolytes, including 
calcium, eGFR and TSH at baseline and then every 6 months (NICE, 2014a), while BAP 
recommends similar tests to be performed once every 12 months (Goodwin et al., 2016). 
A detailed discussion of the recommendations from (and discrepancies between) all 
major international guidelines was recently published by Malhi et al. (2017). In the UK, 
the NICE guidelines are considered to be the ‘golden standard’ as they are based on the 
highest-quality evidence and are strongly supported by government policy (Samanta and 
Gunn, 2003). Therefore, NICE 2014 will be used as the reference standard for this study. 
 
Recently, a systematic review was published identifying 7 audits of lithium monitoring in 
the UK and 1 audit in Ireland dating between 1992 and 2013 (Aubry et al., 2017). This 
review concluded that while lithium monitoring has improved through the years, gaps 
remain between standard recommendation and clinical practice. The largest attempt to 
date to improve lithium monitoring nationally was the Quality Improvement Programme 
(QIP) launched by the Prescribing Observatory for Mental Health (POMH) in response to 
the results of an audit conducted in 2008 (Paton et al., 2010) and alerts by the National 
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Patient Safety Agency (NPSA). Two audits (in 2010 and 2011) were performed to assess 
the programme’s impact, which showed that monitoring of lithium, renal and thyroid 
function had indeed improved since the baseline audit, however, significant gaps still 
remained between recommendation (NICE 2006 at the time) and clinical practice (Paton 
et al., 2013). Further, the co-prescription of drugs that interact with lithium had remained 
common (Paton et al., 2013). The audits performed to date have had varied limitations 
ranging from small sample sizes (Butler and Taylor, 2000; Glover and Lawley, 2005), 
sample selection bias (Paton et al., 2013) and failure to identify the guidelines which 
were used as a reference standard or the use only of local guidelines (Glover and Lawley, 
2005; Kehoe and Mander, 1992; Udumaga and Mannion, 2010; Eagles et al., 2000).  
 
The reasons for poor monitoring suggested by the audits performed so far include: (i) 
patient factors, including inadequate information given to patients regarding the 
importance of monitoring (Collins et al., 2010; Gerrett et al., 2010); (ii) clinician factors, 
including varying willingness to accept guidelines (McKean and Vella-Brincat, 2012; 
Paterniti and Bisserbe, 2013; Perlis, 2007; Samalin et al., 2011); (iii) procedural factors, 
including lack of systems to generate reminders and poor communication between 
primary and secondary care (Aubry et al., 2017; Gerrett et al., 2010); and (iv) the nature 
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of the disease itself, as it has been shown that a third of patients with bipolar disorder 
miss at least 30% of prescribed doses (Sajatovic et al., 2006).  
 
The aims of this study were to determine whether routine lithium monitoring practice 
during maintenance phase treatment in one of the largest mental healthcare organisations 
in Europe - the South London and Maudsley (SLaM) NHS Trust (Jackson et al., 2017), 
reaches the standard set by the most recent NICE guideline (NICE, 2014a). The study 
benchmarks were as follows: 
1. Serum lithium level should be between 0.6-1.0 mmol/l; 
2. Serum lithium level needs to be measured every 6 months; 
3. Renal function and thyroid function tests should be performed every 6 months; 
4. Monitoring of lithium levels should be performed every 3 months for patients at 
an increased risk of toxicity. 
 
Methods 
The dataset 
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The Clinical Record Interactive Search system (CRIS) is a large, reliable and constantly 
updated research database established in 2008 that extracts information from the SLaM 
NHS Trust electronic clinical records system (NIHR-BRC, 2015). SLaM is among 
Europe’s largest mental health trusts, providing care for over 1.2 million people locally, 
in addition to national specialist services. According to recent estimates, the database 
contains the clinical records of more than 250,000 patients and over 3.5 million 
documents (Jackson et al., 2017) with identifiable information removed (e.g. names, 
address, NHS number; DOB restricted to month and year, etc.). Additionally, 
pathological laboratory results have been incorporated into CRIS since January 2012 
from the largest hospital in the Trust (King’s College Hospital), with the aim to expand 
the integration to all laboratories in the area. A detailed description of the database has 
previously been published elsewhere (Stewart et al., 2009; Perera et al., 2016). Lithium 
monitoring practice has not been investigated in this area since this system was 
established.  
 
The sample 
Patients registered with the SLaM NHS Trust were selected for analysis if they met the 
following criteria: (i) aged 18 and above; (ii) had a mental disorder diagnosis (defined by 
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ICD-10 codes); (iii) were registered in the Trust and taking lithium anytime between 
January 2012 and January 2016; (iv) stayed in the service for at least 6 months; and (v) 
had at least one lithium level test during the observation period. The requirement for at 
least one test result in the system was necessary to indicate that monitoring was 
performed in this service. Patients fulfilling the above criteria were included regardless of 
whether they were inpatients, outpatients or both during the observed period. 
 
Patient consent was not required for this study. Approval was obtained from the CRIS 
Oversight Committee and the Mood, Anxiety and Personality Disorder Clinical 
Academic Groups (MAP-CAG) of SLaM NHS Trust. 
 
Data extraction and preparation 
The following data were extracted for patients who met the selection criteria: age, gender, 
primary psychiatric diagnosis, chronic comorbid medical diagnoses, co-prescribed 
medications that interact with lithium as specified by the Joint Formulary Committee (i.e. 
ACE inhibitors, angiotensin II receptor antagonists, calcium channel blockers, 
carbamazepine, COX II inhibitors, SSRIs, loop diuretics, methyldopa, metronidazole, 
NSAIDs, potassium sparing, thiazide, topiramate, acetazolamide, aminophylline, sodium 
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bicarbonate and theophylline) (Joint Formulary, 2015), serum lithium test results, renal 
function and thyroid function test results. Diagnoses and medications data were extracted 
from both free text and fixed fields. Extraction from free text was done with the use of 
natural language processing applications that can recognise a diagnostic statement (not 
speculation over a diagnosis) and a diagnosis that is related to the patient only (not a 
friend/family member etc.). These applications have been previously described elsewhere 
and have demonstrated specificity and sensitivity (Perera et al., 2016). Lab test data were 
extracted from fixed fields only as these are automatically populated into CRIS from the 
lab’s record since 2012. 
 
As it could not be estimated what phase of treatment bipolar patients were in (i.e. under 
which NICE recommendation category they fall under), for the purposes of this study a 
serum level between 0.6-1.0 mmol/l and a measurement taken every 6 months (within a ± 
31 day window) was considered as in keeping with NICE 2014 guidelines. For the sub-
groups of patients at increased risk of toxicity, a test performed every 3 months (± 31 
days) was considered as in keeping with NICE 2014 guidelines. Similarly to a previous 
audit conducted by Collins et al. (2010), multiple test that were conducted within 31 days 
of each other were counted as a single test and their values were removed from the 
13 
 
lithium level test result analysis, as these were considered to be performed for a purpose 
outside of routine maintenance monitoring. Additionally, these could have been 
performed as part of treatment initiation, which is not the focus of this study.  
 
As data on end date of treatment cannot be reliably extracted from CRIS, for the purposes 
of these analyses we calculated the exposure period to lithium for each patient as ‘the 
time from the date of first lab test to the date of last lab test’ recorded in the system. This 
way we could most reliably estimate whether patients were monitored according to the 
schedule recommended by NICE, while they were monitored in SLaM NHS Trust. 
 
Statistical analyses 
Descriptive statistics were used to describe the sample and determine performance 
against the survey benchmarks in terms of serum lithium level and frequency of lithium, 
thyroid function and renal function testing. Regression analyses were performed to 
investigate whether co-prescription, age and comorbidity were associated with 
monitoring performance. All analyses were completed using statistical software (SPSS, 
version 23; IBM Corp, Armonk, NY, USA).  
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Results 
A total of 412 patients who fulfilled the inclusion criteria were retrieved from CRIS. The 
mean age of the sample was 40 years, 210 (51%) were female, 279 (67.7%) had a 
primary diagnosis of (any) bipolar disorder, 129 (31.3%) had an additional chronic 
comorbidity and 251 (60.9%) were co-prescribed a medication interacting with lithium 
(Table 2). Of these, 289 patients only had one serum lithium test result recorded in the 
system. Consequently, these patients could only be included in the lithium level analyses 
and had to be excluded from the frequency of testing analyses. Frequency of lithium 
level, renal and thyroid function testing analyses were performed with the remaining sub-
sample (n=123). The demographic characteristics of this sub-sample are also summarised 
in Table 2.  
 
Table 2: Demographic characteristics of the sample 
Key characteristics Full sample (n=412) 
Sub-sample* 
(n=123) 
Gender Female (%) 210 (51) 59 (48) 
Age Mean age in years (SD) 40.1 (14.4) 41.1 (14.3) 
Median age, years (IQR) 37 (18) 38 (17) 
Age range in years 18 - 89 18-84 
Elderly (>65 years) (%) 32 (7.7) 10 (8.1) 
Ethnicity Asian (%) 29 (7.0) 12 (8.1) 
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Black (%) 105 (25.5) 31 (25.2) 
White (%) 241 (58.5) 69 (56.1) 
Mixed or other (%) 37 (9.0) 13 (10.6) 
Primary 
Diagnosis 
Bipolar disorder (%) 279 (67.7) 83 (67.5) 
Other (%) 128 (31.1) 40 (32.5) 
Chronic 
comorbidity 
Any (%) 129 (31.3) 45 (36.6) 
Hypertension (%) 30 (7.3) 8 (6.5) 
Diabetes (%) 28 (6.8) 9 (7.3) 
Thyroid disorder (%) 20 (4.9) 7 (5.7) 
On medication interacting with lithium** (%) 251 (60.9) 74 (60.2) 
*with >1 lithium level test result; ** any specified in British National Formulary (BNF) (Joint 
Formulary, 2015) 
 
 
Serum lithium level  
For the 412 patients there were 2639 serum lithium level tests. Of these, there were 1337 
(50.7%) within the therapeutic range of 0.6-1.0 mmol/l, 1119 (42.4%) below the range 
and 183 (6.9%) above the range. Numerical serum level result was present in the system 
for 2615 of these tests (see Figure 1 for distribution). The mean lithium level was M=0.65 
(SD=0.26) and the range was between 0.04-2.01mmol/l. There were 324 (78.6%) patients 
who had a sub-optimal lithium level at least once and 73 (17.7%) patients who had at 
least one lithium level above the recommended range. Among those 73 patients, 58.9% 
were co-prescribed at least one medication interacting with lithium and 34.2% had at 
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least one chronic comorbidity (these rates are similar to those in Table 1). Only 0.5% of 
results (n=13, attributable to 10 patients) were above the toxicity cut-off of 1.5mmol/l. 
 
[insert Figure 1.]  Figure 1. Distribution of lithium level test results (n=2615). 
 
 
Frequency of serum lithium level tests and renal and thyroid function tests 
For those patients who had >1 test result in the database (n=123), the recommendation of 
at least one test every 6 months was met for 76.2% of cases for lithium level, 72.7% of 
cases for renal function and 60.2% of cases for thyroid function (Columns 1 & 2, Table 
3). Among these patients, there were 85 patients that met NICE 2014 criteria for 
increased risk of toxicity (i.e. were elderly, had a chronic comorbidity and/or were co-
prescribed at least one medication with a BNF-specified interaction with lithium) and 
have a recommended testing frequency for lithium levels of 3 months. The testing rates 
for this sub-group are presented in Table 3. Regression analyses were performed to 
investigate whether the risk factors co-prescription, age and comorbidity (diabetes, 
hypertension, thyroid disorders) were associated with monitoring performance. These 
were non-significant (P>0.05). 
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Table 3: Number of patients tested at each of the specified frequencies. 
Test 
Frequency of testing 
1-4 months 5-7 months > 7 months 
Lithium level    
All patients  67 (54.9%) 26 (21.3%) 29 (23.8%) 
– >65 years (n=10) 5 (50.0%) 3 (30.0%) 2 (20.0%) 
– On interacting drug* (n=74) 42 (56.8%) 20 (27.0%) 12 (16.2%) 
– With chronic comorbidity** 
(n=23) 11 (47.8%) 5 (21.7%) 7 (30.4%) 
Renal function    
All patients  76 (62.8%) 12 (9.9%) 33 (27.3%) 
Thyroid function    
All patients  52 (42.3%) 22 (17.9%) 47 (38.8%) 
*any medication interacting with lithium listed in the BNF; **hypertension, diabetes 
and/or any thyroid disorder; 
 
 
 
Discussion 
This study aimed to assess whether lithium monitoring during maintenance phase 
treatment in one of the largest mental health trusts in the UK  is performed according to 
the standard set by the latest NICE guidelines for assessment and management of bipolar 
disorder (NICE, 2014a). This is the first study of this kind since the establishment of the 
Clinical Record Interactive Search system (CRIS) database in the South London and 
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Maudsley (SLaM) NHS Foundation Trust. Overall, we found that patients in SLaM have 
a mean serum lithium level of 0.65mmol/l, which closely resembles the level reported by 
other studies and audits in the UK (e.g. 0.63mmol/l in McKean & Vella-Brincat (2012) & 
Paton et al., (2010); and 0.64 mmol/l in Head & Dening (1998)). The main findings show 
that almost half of all serum lithium level tests results were outside of the optimal range. 
There were few lithium levels above range (6.9%). For some of these cases, it is possible 
that the target level was higher due to a more difficult-to-treat illness (Paton et al., 2010). 
There were very few test results above the toxicity level, which is a reassuring finding. 
The high number of tests in this study that were below the therapeutic threshold (42.4%) 
is worrying, as it indicates that these patients may not have been receiving the full 
therapeutic benefit of lithium, which could increase the risk of relapse and also contribute 
to the poor treatment adherence, which is common among this patient group (Mitchell 
and Selmes, 2007). However, due to the nature of the database, we could not investigate 
the potential relationship between sub-therapeutic levels and adverse outcomes (such as 
non-adherence or relapse). Alternatively, poor adherence itself could have contributed to 
the sub-optimal results; however, we had no adherence data available to investigate this 
possibility. The sub-therapeutic levels could also be reflective clinicians’ fear of toxicity, 
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despite the overwhelming evidence in the literature that first signs of toxicity manifest at 
plasma levels above 1.5mmol/l (Oruch et al., 2014).  
 
The latest audit (the post-QIP POMH audit) reported that 86% of last recorded 
measurements for patients were within range (Paton et al., 2013). Reporting on the last 
observed value, however, only captures one time-point of patients’ treatment and is not 
necessarily reflective of a patient’s experience during long-term maintenance treatment. 
Further, this and other previous audits have set the therapeutic range to 0.4-1.0mmol/l. 
Almost 1 in 4 lithium levels in our study were between 0.4-0.6mmol/l which, according 
to the most up-to-date evidence and guidelines, is considered to be ineffective for bipolar 
disorder (Tohen et al., 2005) and also as augmentation for treatment resistant depression 
(Bauer et al., 2013; Cleare et al., 2015). Therefore, it is important that audits are re-
evaluated after major guidelines are updated and Trust and laboratory policies are 
updated accordingly. 
 
The high percentage of co-prescription of interacting drugs (60% of patients were on at 
least one such medication) could also be contributing to the high number of out-of-range 
results. In comparison, the post-QIP POMH audit reported only 9% of co-prescription of 
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such drugs, however, these included only NSAIDs, COX-2 inhibitors, ACE-inhibitors 
and angiotensin-2 receptor antagonists (Paton et al., 2013). In this study, we have 
included the full set of interacting drugs listed in the BNF, which also contains SSRIs 
(Joint Formulary, 2015). This could explain the large difference, as the post-QIP audit 
separately reported 41% co-prescription of an antidepressant in the bipolar patients and 
85% in patients with other affective disorders (Paton et al., 2013). This is intriguing given 
the increasing evidence that antidepressants have limited effect in patient with bipolar 
disorder (Ghaemi et al., 2010; Pacchiarotti et al., 2013). Further studies are merited to 
investigate the high co-prescription observed in this survey and previous audits. While 
there is a theoretical reason to suppose an SSRI-lithium interaction, previous studies have 
demonstrated little potential for a toxic interaction; however, non-serious adverse events 
have been reported to arise frequently (Hawley et al., 2000). Better specificity in the 
NICE guidelines on which groups of interacting medications should be monitored more 
frequently would be useful in this patient group where lithium–SSRI co-prescription is 
common. 
 
In terms of testing frequency, we found that for 76% of patients in this study the current 
NICE monitoring standard was met with lithium levels being measured every 6 months or 
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more frequently. For renal and thyroid tests, 73% and 60% of patients, respectively, were 
tested at the recommended frequency of 6 months or more often. In comparison with the 
most recent audits, monitoring performance is very similar to the post-QIP POMH audit 
(Paton et al., 2013) and poorer than in the Norfolk audit (following implementation of a 
regional lithium register and database) (Kirkham et al., 2013). Among the sub-groups at 
an increased risk of toxicity, there were too few patients over the age of 65 or with a 
chronic co-morbidity to draw meaningful conclusions. With regards to co-prescribed 
interacting medication, only 56.8% of patients on any such medication had lithium levels 
tested every 3 months, as indicated by NICE 2014. These, however, also include patients 
on SSRIs, the controversy of which was discussed above.  
 
In this survey, there was a high number of patients (289 of 412) for whom there was only 
one serum lithium test recorded in the system. It is extremely unlikely that such a high 
proportion of patients were not monitored at all. A possible explanation is that for these 
patients routine monitoring was performed in other labs across the Trust (results from 
which are not integrated into CRIS), or more likely, in primary care. Such information 
was not available to us from the system. Indeed, some NICE guidelines (e.g. for the 
prevention and management of psychosis and schizophrenia;(NICE, 2014b) were recently 
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updated to regulate the responsibility of monitoring the physical health of patients with 
severe mental illness and to establish a role for primary care in monitoring particularly 
during maintenance phase treatment. Given that SLaM is one of the largest mental health 
Trusts in the UK, it should be clearer from patient electronic records where and by whom 
routine monitoring is being performed. This could be achieved through the development 
of Trust-wide shared-care agreements, an electronic reminder system for 
secondary/tertiary care or a central registry of all patients on lithium (e.g. similar to the 
clozapine system). Similar strategies have previously been attempted in smaller settings 
(Kirkham et al., 2013; Eagles et al., 2000) and have been shown to reduce the 
discrepancies between guideline recommendation and clinical practice (Aubry et al., 
2017). 
 
This study had several limitations, mainly stemming from the nature of the database used. 
First, as there are no dispensing records in the database, treatment adherence and any 
potential gaps in treatment could not be investigated. Second, initial start date of 
treatment and whether patients were first-time users could not be inferred with certainty. 
Third, as GP records are not integrated in the system, the role of primary care in the 
routine monitoring of patients in SLaM could not be assessed. Fourth, due to the 
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limitations of the database, there may be an inherent selection bias to the sample (e.g. the 
sample is limited to patients tested in one laboratory within the Trust), even if this was 
not intentionally imposed by the researchers. Further, this study did not look at 
parathyroid monitoring and future studies and audits should also examine frequency of 
calcium tests. Finally, a general limitation of retrospective observational analyses is that 
the reasons behind any observed non-adherence to the NICE guidelines cannot be 
determined with certainty. Conversely, the strengths of this study include: (i) clearly 
defined parameters based on the latest NICE guidelines; (ii) the use of a large, constantly 
updated and growing database of clinical records; (iii) diverse population of patients from 
one of the largest mental health trusts in the UK; (iv) the use of a retrospective 
observational cohort eliminates the recall bias that previous surveys have been criticised 
for. 
Conclusion 
Lithium monitoring remains sub-optimal with rates of serum lithium level, renal and 
thyroid function tests falling short from the current NICE recommendation. The high 
number of test results below the therapeutic minimum is concerning, as it can play a 
pivotal role in treatment non-adherence and relapse. Clinical practice should actively 
update to meet the most recent evidence-based guidelines which recommend that levels 
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above 0.6mmol/l should be maintained during maintenance phase treatment. Further, 
electronic reminder systems for secondary/tertiary care clinicians, shared care agreements 
or a central registry for lithium users should be implemented in order to improve 
monitoring performance in secondary care.  
Acknowledgements 
CRIS is supported by the NIHR Biomedical Research Centre for Mental Health BRC 
Nucleus at the South London and Maudsley NHS Foundation Trust and Institute of 
Psychiatry, Psychology and Neuroscience, King’s College London jointly funded by the 
Guy’s and St Thomas’ Trustees and the South London and Maudsley Trustees. 
 
Funding 
The authors received no specific financial support for the research, authorship, and/or 
publication of this article. Professor Young’s research is funded by the National Institute 
for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley 
NHS Foundation Trust and King’s College London. Dr Mazzei was indirectly supported 
by a Río Hortega grant (CM15/00127) from Instituto de Salud Carlos III, Spain. 
Professor Taylor’s research is funded by the NHS and King’s College London. The views 
expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the 
Department of Health. 
 
Declaration of conflicting interest 
Professor Allan Young: paid lectures and advisory boards for the following companies: 
AstraZeneca, Eli Lilly, Janssen, Lundeck, Sunovion, Servier, Livanova; Investigator 
initiated studies from AstraZeneca, Eli Lilly, Lundbeck, Wyeth. Professor David Taylor: 
25 
 
advisory board member of Allergan; research funding from Janssen, Lundbeck, 
Sunovion; lectures for Janssen, Otsuka, Servier, Lundbeck, Sunovion.  
 
References 
Aubry RE, Scott L and Cassidy E. (2017) Lithium monitoring patterns in the United 
Kingdom and Ireland: Can shared care agreements play a role in improving 
monitoring quality? A systematic review. Irish Journal of Psychological Medicine 
34: 127-140. 
Baird-Gunning J, Lea-Henry T, Hoegberg LCG, et al. (2016) Lithium poisoning. J 
Intensive Care Med. 
Bauer M, Dell'osso L, Kasper S, et al. (2013) Extended-release quetiapine fumarate 
(quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to 
antidepressants in patients with treatment-resistant major depressive disorder. J 
Affect Disord 151: 209-219. 
Butler and Taylor. (2000) A survey of monitoring and prescribing patterns. International 
Journal of Psychiatry in Clinical Practice: 135-138. 
Cade JF. (1949) Lithium salts in the treatment of psychotic excitement. Med J Aust: 349-
352. 
Cleare A, Pariante CM, Young AH, et al. (2015) Evidence-based guidelines for treating 
depressive disorders with antidepressants: A revision of the 2008 British 
Association for Psychopharmacology guidelines. J Psychopharmacol 29: 459-
525. 
Collins N, Barnes TR, Shingleton-Smith A, et al. (2010) Standards of lithium monitoring 
in mental health Ttrusts in the UK. BMC Psychiatry: 80. doi 10.1186/1471-
1244X-1110-1180. 
Crossley NA and Bauer M. (2007) Acceleration and augmentation of antidepressants 
with lithium for depressive disorders: two meta-analyses of randomized, placebo-
controlled trials. J Clin Psychiatry: 935-940. 
Eagles JM, McCann I, MacLeod TN, et al. (2000) Lithium monitoring before and after 
the distribution of clinical practice guidelines. Acta Psychiatr Scand 101: 349-
353. 
26 
 
Gerrett D, Lamont T. , Paton C. , et al. (2010) Prescribing and monitoring lithium 
therapy: summary of a safety report from the National Patient Safety Agency. 
Bmj: c6258. 
Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. (2010) Antidepressant discontinuation 
in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar 
Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and 
safety. J Clin Psychiatry 71: 372-380. 
Gitlin M. (2016) Lithium side effects and toxicity: prevalence and management 
strategies. International Journal of Bipolar Disorders 4: 27. 
Glover KJ and Lawley D. (2005) How safe is lithium prescribing? Audit of a local 
prescribing framework and patient survey. Psychiatric Bulletin 29: 98-100. 
Goodwin GM, Haddad P. M., Ferrier I. N. , et al. (2016) Evidence-based guidelines for 
treating bipolar disorder: Revised third edition recommendations from the British 
Association for Psychopharmacology. 
Grunze H, Vieta E. , Goodwin G. M., et al. (2009) The World Federation of Societies of 
Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar 
disorders: update 2009 on the treatment of acute mania. The World Journal of 
Biological Psychiatry: 85-116. 
Grunze H, Vieta E. , Goodwin G. M. , et al. (2013) The World Federation of Societies of 
Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar 
disorders: update 2012 on the long-term treatment of bipolar disorder. The World 
Journal of Biological Psychiatry: 154-219. 
Hawley CJ, Loughlin PJ, Quick SJ, et al. (2000) Efficacy, safety and tolerability of 
combined administration of lithium and selective serotonin reuptake inhibitors: a 
review of the current evidence. Hertfordshire Neuroscience Research Group. Int 
Clin Psychopharmacol 15: 197-206. 
Hayes JF, Marston L, Walters K, et al. (2016a) Adverse Renal, Endocrine, Hepatic, and 
Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar 
Disorder: A Population-Based Cohort Study. PLOS Medicine 13: e1002058. 
Hayes JF, Pitman A, Marston L, et al. (2016b) Self-harm, Unintentional Injury, and 
Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment: A 
UK Population-Based Electronic Health Records Study. JAMA Psychiatry 73: 
630-637. 
Jackson RG, Patel R, Jayatilleke N, et al. (2017) Natural language processing to extract 
symptoms of severe mental illness from clinical text: the Clinical Record 
27 
 
Interactive Search Comprehensive Data Extraction (CRIS-CODE) project. BMJ 
Open 7. 
Joint Formulary C. (2015) British national formulary 70, London: BMJ Publishing and 
the Royal Pharmaceutical Society. 
Kehoe RF and Mander AJ. (1992) Lithium treatment: prescribing and monitoring habits 
in hospital and general practice. British Medical Journal 304: 552-554. 
Kirkham E, Bazire S, Anderson T, et al. (2013) Impact of active monitoring on lithium 
management in Norfolk. Therapeutic Advances in Psychopharmacology 3: 260-
265. 
Kraszewska A, Abramowicz M., Chlopocka-Wozniak M. , et al. (2014) The effect of 
lithium on thyroid function in patients with bipolar disorder. Psychiatr Pol: 417-
428. 
Malhi GS, Bassett D., Boyce P., et al. (2015) Royal Australian and New Zealand College 
of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J 
Psychiatry: 1087-1206. 
Malhi GS, Gessler D and Outhred T. (2017) The use of lithium for the treatment of 
bipolar disorder: Recommendations from clinical practice guidelines. J Affect 
Disord 217: 266-280. 
Malhi GS and Outhred T. (2016) Therapeutic Mechanisms of Lithium in Bipolar 
Disorder: Recent Advances and Current Understanding. CNS Drugs 30: 931-949. 
McKean A and Vella-Brincat J. (2012) Is it NICE to monitor lithium routinely. N Z Med 
J: 50-54. 
McKnight RF, Adida M., Budge K., et al. (2012) Lithium toxicity profile: a systematic 
review and meta-analysis. Lancet: 721-728. 
Meyer JS and Quenzer LF. (2013) Psychopharmacology: drugs, the brain, and behavior 
(2nd ed.), Sunderland, Mass.: Sinauer Associates. 
Mitchell AJ and Selmes T. (2007) Why don’t patients take their medicine? Reasons and 
solutions in psychiatry. Advances in Psychiatric Treatment 13: 336-346. 
Miura T, Noma H, Furukawa TA, et al. (2014) Comparative efficacy and tolerability of 
pharmacological treatments in the maintenance treatment of bipolar disorder: a 
systematic review and network meta-analysis. The Lancet Psychiatry 1: 351-359. 
Mowry JB, Spyker DA, Cantilena LR, et al. (2013) 2012 Annual report of the American 
association of poison control centers’ national poison data system (NPDS): 30th 
annual report. Clin Toxicol. 51. 
NICE. (2014a) Bipolar disorder: assessment and management. Available at: Retrieved 
from https://www.nice.org.uk/guidance/cg185. 
28 
 
NICE. (2014b) Psychosis and schizophrenia in adults: prevention and management. 
Available at: https://www.nice.org.uk/guidance/cg178. 
NIHR-BRC. (2015) What is CRIS. Available at: Retrieved July, 2, 2016, from 
http://www.maudsleybrc.nihr.ac.uk/about-us/core-facilities/clinical-record-
interactive-search-cris/what-is-cris/. 
Oruch R, Elderbi MA, Khattab HA, et al. (2014) Lithium: A review of pharmacology, 
clinical uses, and toxicity. European Journal of Pharmacology 740: 464-473. 
Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. (2013) The International Society for 
Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar 
disorders. Am J Psychiatry 170: 1249-1262. 
Paterniti S and Bisserbe JC. (2013) Pharmacotherapy for bipolar disorder and 
concordance with treatment guidelines: survey of a general population sample 
referred to a tertiary care service. BMC Psychiatry: 211. doi 210.1186/1471-
1244X-1113-1211. 
Paton C, Adroer R. and Barnes TR. (2013) Monitoring lithium therapy: the impact of a 
quality improvement programme in the UK. Bipolar Disord: 865-875. 
Paton C, Barnes T. R., Shingleton-Smith A. , et al. (2010) Lithium in bipolar and other 
affective disorders: prescribing practice in the UK. J Psychopharmacol: 1739-
1746. 
Perera G, Broadbent M, Callard F, et al. (2016) Cohort profile of the South London and 
Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case 
Register: current status and recent enhancement of an Electronic Mental Health 
Record-derived data resource. BMJ Open 6: e008721. 
Perlis RH. (2007) Use of treatment guidelines in clinical decision making in bipolar 
disorder: a pilot survey of clinicians. Curr Med Res Opin: 467-475. 
Sajatovic M, Bauer MS, Kilbourne AM, et al. (2006) Self-reported medication treatment 
adherence among veterans with bipolar disorder. Psychiatr Serv 57: 56-62. 
Samalin L, Guillaume S., Auclair C., et al. (2011) Adherence to guidelines by French 
psychiatrists in their real world of clinical practice. J Nerv Ment Dis: 239-243. 
Samanta ASJ and Gunn M. (2003) Legal considerations of clinical guidelines: will NICE 
make a difference. J R Soc Med: 133-138. 
Song J, Sjölander A, Joas E, et al. (2017) Suicidal Behavior During Lithium and 
Valproate Treatment: A Within-Individual 8-Year Prospective Study of 50,000 
Patients With Bipolar Disorder. The American Journal of Psychiatry: 
appiajp201716050542. 
29 
 
Stahl SM. (2013) Stahl's essential psychopharmacology: neuroscientific basis and 
practical application (4th ed.), Cambridge: Cambridge University Press. 
Stewart R, Soremekun M, Perera G, et al. (2009) The South London and Maudsley NHS 
Foundation Trust Biomedical Research Centre (SLAM BRC) case register: 
development and descriptive data. BMC Psychiatry 9: 51. 
Storosum JG, Wohlfarth T, Schene A, et al. (2007) Magnitude of effect of lithium in 
short-term efficacy studies of moderate to severe manic episode. Bipolar Disord 
9: 793-798. 
Taylor D, Paton C. and Kapur S. (2015) The Maudsley Prescribing Guidelines in 
Psychiatry, 12th Edition: Wiley-Blackwell. 
Tohen M, Greil W., Calabrese J. R, et al. (2005) Olanzapine versus lithium in the 
maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, 
controlled clinical trial. Am J Psychiatry: 1281-1290. 
Udumaga E and Mannion L. (2010) An audit in general adult psychiatry service. Ir Med J 
103: 123-124. 
Waring WS, Laing WJ, Good AM, et al. (2007) Pattern of lithium exposure predicts 
poisoning severity: evaluation of referrals to a regional poisons unit. Qjm 100: 
271-276. 
Yatham LN, Kennedy S. H. , Parikh S. V. , et al. (2013) Canadian Network for Mood and 
Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders 
(ISBD) collaborative update of CANMAT guidelines for the management of 
patients with bipolar disorder: update 2013. Bipolar Disord: 1-44. 
 
 
